Action ARVN ARVINAS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Arvinas, Inc.

Actions

ARVN

US04335A1051

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
31,77 USD -0,41% Graphique intraday de Arvinas, Inc. -6,56% -22,81%
24/04 Arvinas, Inc. nomme Randy Teel au poste de Chief Business Officer CI
15/04 ARVINAS, INC. : HC Wainwright optimiste sur le dossier ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer
Arvinas : 2024 Proxy Statement
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Novartis : accord de licence dans le cancer de la prostate
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten
Novartis licenses Arvinas' cancer drug for up to $1 billion
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee
Arvinas to Participate in Upcoming Investor Conferences
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARVN
  4. Actualités Arvinas, Inc.
  5. Autres langues